The therapeutic value and safety of icotinib as first-line therapy for advanced non-small cell lung ;cancer patients
10.3760/cma.j.issn.0578-1426.2017.01.010
- VernacularTitle:盐酸埃克替尼一线治疗晚期非小细胞肺癌的疗效与安全性
- Author:
Hui CHEN
;
Hanping WANG
;
Li ZHANG
;
Xiaoyan SI
- Keywords:
Icotinib;
Carcinoma,non-small cell lung;
Treatment outcome;
Safety
- From:
Chinese Journal of Internal Medicine
2017;56(1):39-43
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of icotinib as first-line therapy in Chinese non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) sensitive mutations.Methods Patients with stage ⅢB/Ⅳ NSCLC who had EGFR sensitive mutation and had no previous treatment were enrolled into this study.The response rates , progress free survival ( PFS) , overall survival ( OS ) , and the safety were analyzed.Results Ninety advanced adenocarcinoma patients were enrolled in this study , 44 patients had partial response ( PR ) , 42 patients had stable disease ( SD ) , 4 patients had progressive disease (PD), with an overall response rate (ORR) of 48.9%, and a disease control rate (DCR) of 95.6%.The median PFS was 14.9 months (95%CI 13.5-16.3) and the OS was 37.0 weeks ( 95%CI 27.9 -46.1 ).Patients with brain metastases showed higher ORR ( P =0.049 ).Patients with stage ⅢB had longer PFS than those with stage Ⅳ( P=0.007 ).The most common adverse events were grade 1 -2 skin rash (38 patients, 40.9%).Other adverse events included dry skin , oral mucositis, diarrhea and liver function injury.Three patients withdrew because of severe liver injury or skin rash.No treatment related mortality occurred .Conclusions Icotinib is effective and safe as first-line treatment for Chinese advanced NSCLC patients with EGFR sensitive mutation.
